Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Equity Ratio (2016 - 2025)

Ani Pharmaceuticals' Equity Ratio history spans 16 years, with the latest figure at 0.38 for Q4 2025.

  • For Q4 2025, Equity Ratio rose 19.45% year-over-year to 0.38; the TTM value through Dec 2025 reached 0.38, up 19.45%, while the annual FY2025 figure was 0.38, 19.45% up from the prior year.
  • Equity Ratio for Q4 2025 was 0.38 at Ani Pharmaceuticals, up from 0.36 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.58 in Q2 2024 and bottomed at 0.13 in Q4 2022.
  • The 5-year median for Equity Ratio is 0.01 (2022), against an average of 0.17.
  • The largest YoY upside for Equity Ratio was 7878.12% in 2023 against a maximum downside of 3554.6% in 2023.
  • A 5-year view of Equity Ratio shows it stood at 0.5 in 2021, then tumbled by 125.46% to 0.13 in 2022, then soared by 107.65% to 0.01 in 2023, then surged by 3109.21% to 0.31 in 2024, then grew by 19.45% to 0.38 in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Equity Ratio are 0.38 (Q4 2025), 0.36 (Q3 2025), and 0.06 (Q2 2025).